» Articles » PMID: 29134744

Acute Oral Sodium Propionate Supplementation Raises Resting Energy Expenditure and Lipid Oxidation in Fasted Humans

Overview
Specialty Endocrinology
Date 2017 Nov 15
PMID 29134744
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Short-chain fatty acids (SCFAs), produced from fermentation of dietary fibre by the gut microbiota, have been suggested to modulate energy metabolism. Previous work using rodent models has demonstrated that oral supplementation of the SCFA propionate raises resting energy expenditure (REE) by promoting lipid oxidation. The objective of the present study was to investigate the effects of oral sodium propionate on REE and substrate metabolism in humans. Eighteen healthy volunteers (9 women and 9 men; age 25 ± 1 years; body mass index 24.1 ± 1.2 kg/m ) completed 2 study visits following an overnight fast. Tablets containing a total of 6845 mg sodium propionate or 4164 mg sodium chloride were provided over the 180-minute study period in random order. REE and substrate oxidation were assessed by indirect calorimetry. Oral sodium propionate administration increased REE (0.045 ± 0.020 kcal/min; P = .036); this was accompanied by elevated rates of whole-body lipid oxidation (0.012 ± 0.006 g/min; P = .048) and was independent of changes in glucose and insulin concentrations. Future studies are warranted to determine whether the acute effects of oral sodium propionate on REE translate into positive improvements in long-term energy balance in humans.

Citing Articles

Gut microbiota-derived short chain fatty acids act as mediators of the gut-liver-brain axis.

Li C, Yao J, Yang C, Yu S, Yang Z, Wang L Metab Brain Dis. 2025; 40(2):122.

PMID: 39921774 DOI: 10.1007/s11011-025-01554-5.


Oral supplementation with propionate is reflected in the serum of healthy individuals.

Schroder M, Pasic A, Hirche F, Rozanova S, Sgodzai M, Gisevius B Ther Adv Neurol Disord. 2025; 18:17562864241309755.

PMID: 39866754 PMC: 11758918. DOI: 10.1177/17562864241309755.


Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Hamamah S, Iatcu O, Covasa M Nutrients. 2025; 17(1.

PMID: 39796579 PMC: 11722922. DOI: 10.3390/nu17010143.


Multifaceted Impact of SGLT2 Inhibitors in Heart Failure Patients: Exploring Diverse Mechanisms of Action.

Piperis C, Marathonitis A, Anastasiou A, Theofilis P, Mourouzis K, Giannakodimos A Biomedicines. 2024; 12(10).

PMID: 39457625 PMC: 11504660. DOI: 10.3390/biomedicines12102314.


Systems Biology of Human Microbiome for the Prediction of Personal Glycaemic Response.

Kirtipal N, Seo Y, Son J, Lee S Diabetes Metab J. 2024; 48(5):821-836.

PMID: 39313228 PMC: 11449821. DOI: 10.4093/dmj.2024.0382.


References
1.
Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T . The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013; 4:1829. PMC: 3674247. DOI: 10.1038/ncomms2852. View

2.
De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A . Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014; 156(1-2):84-96. DOI: 10.1016/j.cell.2013.12.016. View

3.
Psichas A, Sleeth M, Murphy K, Brooks L, Bewick G, Hanyaloglu A . The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond). 2014; 39(3):424-9. PMC: 4356745. DOI: 10.1038/ijo.2014.153. View

4.
Flint H, Scott K, Duncan S, Louis P, Forano E . Microbial degradation of complex carbohydrates in the gut. Gut Microbes. 2012; 3(4):289-306. PMC: 3463488. DOI: 10.4161/gmic.19897. View

5.
den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk T . Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation. Diabetes. 2015; 64(7):2398-408. DOI: 10.2337/db14-1213. View